This study is a comparative, double blind, placebo controlled trial of 6-months duration
designed to evaluate 1) the effects of fluoxetine in 5 to 12 years old autistic children, 2)
the effects of fluoxetine on serotoninergic parameters, 3) cerebral metabolic changes (rCBF
measurements with PET) induced by the treatment.